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ABSTRACT
Neuropathological and cell culture studies suggest that tau and ?-synuclein (?-
syn) pathologies may promote each other. In order to study the interaction
between tau and ?-syn more in detail we used adeno-associated virus (AAV)-
vector mediated expression of human wild-type or mutated (P301S) tau in either
wild-type or A30P mice. Green fluorescent protein (GFP) transduction was used
as a control. Local infusions of AAV-vector were made bilaterally into the
hippocampus. The mice were perfused for histology 11 weeks after the gene
transduction. Neuronal loss and tau hyperphosphorylation analyses were done
using a conventional light microscope. Co-localization analyses were done under
a confocal microscope.
Tau transduction was not associated with marked neuronal loss, although a small
decline in the pyramidal cell density was detected in A30P mice receiving wt tau
injections. We also detected hyperphosphorylated tau in a subset of neuronal cell
bodies in the CA3 area in mice with Tau13 positive cells. Of these tau-positive
neurons, 18% in A30P mice but only 7% in wild-type mice receiving human wild-
type tau transduction formed paired helical filament-1 (PHF-1) positive
cytoplasmic densities, while only less than 5% of tau-positive neurons were also
PHF-1 positive after transduction with P301S tau in mice of either genotype.
Cytoplasmic ?-syn positive inclusions were detected in pyramidal cell bodies in
A30P mice transduced with either wild-type or P301S mutated human tau.
3In conclusion, tau and ?-syn proteins interact in vivo and their interaction
promotes a-syn aggregation and tau hyperphosphorylation. However, this
interaction inducing tau hyperphosphorylation is dependent on specific binding
site on tau, and that mutation at the 301 site prevents this interaction.
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5ABBREVIATIONS
?-syn                         ?-synuclein
AAV                         Adeno-associated virus
AD                            Alzheimer's disease
auto                           Automatic counting of both sides
auto_L                      Automatic counting of left side
auto_R                      Automatic counting of right side
BSA                          Bovine serum albumin
DAB-Ni                    3,3'-Diaminobenzidine with nickel
DAPi                         4',6-diamidino-2-phenylindole
DG                            Dentate gyrus
GFP                          Green fluorescent protein
GSK-3beta               Glycogen synthase kinase 3 beta
KPBS-T                    Kallium phosphate buffered saline with triton
LBD                          Lewy body dementia
MAP                         Microtubule associated protein
man_1                       First time manual counting of both sides
man_1L                     First time manual counting of left side
man_1R                     First time manual counting of right side
man_2                       Second time manual counting of both sides
man_2L                    Second time manual counting of left side
man_2R                    Second time manual counting of right side
NFT                          Neurofibrillary tangles
PB                             Phosphate buffer
6PBS                           Phosphate buffered saline
PD                             Parkinson’s disease
PHF                           Paired helical filaments
TBS-T                       Tris buffered saline with triton
tg-GFP                       A30P ?-syn transgenic mice injected with AAV
                                   vector carrying GFP
tg-wt tau                    A30P ?-syn transgenic mice injected with AAV
                                  vector carrying wild type tau
tg-m tau                     A30P ?-syn transgenic mice injected with AAV
                                  vector carrying mutated tau
wt-GFP                     Wild type transgenic mice injected with AAV
                                  vector carrying GFP
wt-wt tau                   Wild type transgenic mice injected with AAV
                                  vector carrying wild type tau
wt-m tau                    Wild type transgenic mice injected with AAV
                                   vector carrying mutated tau
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91. INTRODUCTION
Parkinson’s disease (PD) is a common neurodegenerative disorder, with the
highest prevalence in people aged sixty or older (1). Lewy body dementia (LBD),
also  known  as  dementia  with  Lewy  bodies,  causes  a  progressive  dementia  with
significant cognitive fluctuations and PD-like symptoms (2). ?-Synuclein is an
abundant presynaptic protein which is pathologically linked to PD (3). Tau is a
microtubule-bound protein, which may become hyperphosphorylated by the
imbalance of kinase and phosphatase activities in neurons, leading to formation of
neurofibrillary tangles (4).
Both Parkinson’s disease and Lewy body dementia are characterized by
intracellular accumulation and aggregation of ?-synuclein into Lewy bodies.
Recent evidence suggests that besides ?-synuclein, tau aggregates are also found
in post-mortem brain examination of both diseases (5, 6). Furthermore, a recent
study showed that in vitro, tau and ?-syn induced each other’s polymerization into
fibrils, and in vivo,??-syn promoted the fibrillization of tau in brain sections from
transgenic mice overexpressing human A53T mutated ?-syn (7). These findings
may provide a possible mechanistic explanation for the co-existing of ?-synuclein
and tau. In addition, phosphorylated tau in parallel with accumulation of
aggregated ?-syn were also found in mice overexpressing another ?-syn mutation
(A30P) (8). Another recent study provided additional evidence for the interaction
of ?-syn and tau by showing selective dose-dependent hyperphosphorylation of
tau at Ser396/404 by the treatment of primary mesencephalic neurons or wild-type
mice with the neurotoxin MPP(+)/MPTP. However, this hyperphosphorylated tau
was not observed in transfected cells not expressing ?-syn or in ?-synuclein -/-
mice (9). The kinase involved in this tau hyperphosphorylation , may be glycogen
synthase kinase 3 beta ( GSK-3beta ),because GSK-3beta activation was observed
in many MPP(+)/MPTP models of PD, but there is no evidence of GSK-3 beta
activation in cells not expressing ?-synuclein or in ?-syn KO mice (10). In
addition, it has also been demonstrated that tau overexpression increases ?-syn
aggregation in co-transfected cells (11).
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To study the interaction between these two proteins more in detail we used AAV-
vector mediated expression of human wild-type or mutated (P301S) tau in either
wild-type mice or mice carrying familial PD-linked A30P ?-syn mutation. Local
infusion of AAV-vector were made bilaterally into the hippocampus, because the
endogenous expression levels of ?-syn in the A30P mouse (12) is the highest in
mossy fibers connecting the dentate granule cells with CA3 pyramidal cells.
2. LITERATURE REVIEW
2.1 ?-SYNUCLEIN
2.1.1 Brief introduction
?-Syn is a small (19 kDa) and conserved acidic protein, which is concentrated
mainly in presynaptic axon terminals(13, 14). It appears physiologically in soluble
membrane and lipid-bound fractions (15). ?-Syn is encoded by its gene SNCA,
also known as PARK1, which is located on chromosome 4q21 (16). It  is  a
member of naturally unfolded proteins which do not contain a typical secondary
structure (17). ?-Syn has seven imperfect 11-residue repeat sequences, which are
predicted to form five amphipathic helices on the amino-terminal half in its
primary structure (18, 19, 20). ?-Syn helices 1-4 are expected to be connected
with lipid vesicles (21, 22), whilst helix 5 is likely to be related with protein-
protein interactions (23). However, the secondary structure of ?-syn is dependent
on its environment, which makes ?-syn very dynamic (22, 23).
?-Syn possibly works as a molecular chaperone, which has the ability of binding
to other intracellular proteins due to its complicated biochemical structure (24).
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Two findings strongly support this prediction. First, ?-syn and the 14-3-3 family
of molecular chaperone proteins share the same structural homology (24, 25).
Second, ?-syn expression is upregulated during periods of strengthened neuronal
activity and plasticity (26, 27). Consistent with the chaperone prediction, ?-syn
interacts with numerous proteins and regulates dopamine homeostasis in
nigrostratial dopamine neurons at axon terminals that may have the ability of
regulating the monoaminergic vesicle content and the deposit of nerve terminal
dopamine (28, 29). ?-Syn may also play a role in terminating dopamine
neurotransmission, because its expression changes dopamine transporter-mediated
uptake of synaptic dopamine (30). The phosphorylation of ?-syn regulates the
catalytic activity of tyrosine hydroxylase, the rate-limiting enzyme in dopamine
synthesis (31, 32). ?-Syn takes a paramount role in the mediation of substrate-
dependent increase of phosphorylated tyrosine hydroxylase and dopamine
synthesis in nigrostratial dopamine neurons. It is directly related to dopamine
replenishment and the differentiation of presynaptic dopamine (31, 32, 33). ?-Syn
is also capable of downregulating the p53 pathway to achieve an antiapoptotic
function (34).
2.1.2 The role of ?-synuclein in neurodegenerative diseases
Abnormal ?-syn aggregation has been discovered in many neurodegenerative
diseases. ?-Syn aggregation and its antibodies have been identified in Down
syndrome brains and in Alzheimer's disease (AD) (35). Pathological ?-syn
aggregates have also been found in PD and LBD patients (36). ?-Syn was found
to be the predominant protein in Lewy bodies in sporadic as well as in familial PD
(37, 38, 39, 40), and the filamentous aggregation of ?-syn was detected in LBD
(39, 41). ?-Syn was also found to be extensively nitrated in pathological lesions of
LBD (42,43). Most of ?-syn in Lewy bodies is serine (Ser)-phosphorylated and
residue Ser-129 is the phosphorylation site of approximately 90% of the ?-syn in
Lewy bodies (44). In PD, Lewy body formation and neuronal death are mostly
found in the substantia nigra, although ?-syn is widely expressed throughout the
central nervous system. This is possibly because dopamine metabolism and ?-syn
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conformations interact with each other , causing the selective dopamine loss in PD
(45). There is evidence showing that ?-syn could be a presynaptic regulator of
dopamine secretion, storage or synthesis (46). This has been proved by  showing
that overexpression of ?-syn, both in vitro and in vivo, decreases the activity of
tyrosine hydroxylase and causes a corresponding reduction of dopamine levels
that are not created by the increase in dopamine catabolism or efflux (47). Several
studies indicate that the modification and aggregation of ?-syn play a key role in
neuronal cell death and Lewy body formation related with PD (48).
Hyperphosphorylated ?-syn is found in Lewy bodies and Lewy neurites, which
contributes in important ways to PD process. The role of ?-syn phosphorylation in
neurodegenerative pathogenesis is starting to be revealed by studies of its
phosphatases and kinases (49).
2.2    TAU
2.2.1 Brief introduction
Tau was found to be the first microtubule associated protein (MAP) that promotes
microtubule assembly in vitro (50). Tau protein constitutes a group of closely
connected isoforms which are partly created by alternative mRNA splicing (51).
Tau is usually concentrated in axons (52, 53, 54), but it has been also identified in
the somato-dendritic compartment in a pathological condition (55, 56). Tau
proteins have been found to consist of three domains by different kinds of
functional analysis including integrating sequence comparison. These three
domains are a middle region full of proline that contains corresponding kinases
recognizing sites, a highly acidic amino terminal domain that is accentuated from
the microtubule surface on which it works with other cytoskeletal elements, and a
carboxy terminal domain, which has microtubule binding activity due to its
components of three or four duplicates of a highly conserved 18 amino acid
sequence (57, 58, 59).
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In vitro, tau has the ability to induce nucleation and growth of microtubules and
cause their bundle formation (59). In addition, tau is able to decrease the dynamic
instability of microtubuli (57, 60). Furthermore, in vivo studies demonstrated that
microinjection of tau into fibroblast cells promoted tubulin polymerization and
microtubuli stabilization (61), and that transfection of tau cDNA and the later
expression of tau protein caused microtubule stabilization and bundling in
nonneuronal cells (62, 63, 64). Tau protein is very important in mediating
neuronal outgrowth, axonal transport and dynamic stability of microtubuli. It
accomplishes these functions by the modulation of its site-specific
phosphorylation (65).
2.2.2 The role of tau in neurodegenerative diseases
The aggregation of tau plays an important role in many neurodegenerative
diseases, such as fronto- temporal dementia, AD, and PD. Tau aggregates usually
exists  in  the  form  of  neurofibrillary  tangles  (NFT),  which  contain
hyperphosphorylated tau in the form of twisted or straight filaments or paired
helical filaments (PHF) (66). It has been reported that in AD the number of NFT
in the neocortex reflects the severity of the dementia (67). In frontotemporal
dementia, formation of tau filaments is accelerated due to missense mutations in
tau (68, 69, 70). It could be concluded that tau aggregation induces neuronal cell
death, because many studies have revealed that without aggregation-inducer, tau
over-expression does not cause toxicity (66). The increased ability of tau to
aggregate into filaments in glia and neurons in various tauopathies possibly
derives from the fact that the pool of tau which could form aggregation is
promoted by the pathological status of neurons. Notably, tau fibrillization needs a
high concentration of tau in many experimental models (66).
It is unlikely that the concentration of tau in different kinds of human tauopathies
is as high as in cell culture or in transgenic mice in which tau overexpression was
artificially induced, even though enhanced tau concentration have been shown in
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the AD brain samples (66, 71). For instance, in transgenic mice expressing
mutated human tau, tau aggregation displaced many cytoplasmic organelles from
their normal site and reduced their number in neuronal cells (72).
Hyperphosphorylation of tau is thought to be the first pathological even leading to
the development of NFTs in human tauopathies (73). In the AD brain,
hyperphosphorylated tau appears in the form of straight filaments, paired helical
filaments  or  NFTs  (71,  74). Increased level of tau phosphorylation has also
frequently been found in the cerebrospinal fluid of AD patients, which makes the
increased level of hyperphosphorylated tau a clinically useful diagnostic marker
(75, 76).
2.3 INTERACTION BETWEEN ?-SYNUCLEIN AND TAU
IN NEURODEGENERATIVE DISEASES
Neurodegenerative disorders, such as frontotemporal degeneration, prion diseases,
Huntington’s disease, PD and AD, belong to “proteinopathies”, because they have
common molecular and cellular mechanisms, which include the accumulation of
proteins in the central nervous system (77, 78).
Tau and ?-syn proteinaceous inclusions have been identified as hallmarks of AD
and PD, respectively (79). ?-Syn and tau may coaggregate in the same cell or
same region of the brain in both transgenic mice and humans (80, 81, 6, 82).
There is data suggesting that the oxidative modification of ?-syn plays an
important role in tau aggregation (83), and that the toxic interactions between tau
and ?-syn may cause tau hyperphosporylation and eventually lead to the
deposition  of  both  of  these  two  proteins (84). Tau aggregates were found to be
phosphorylated at Ser 262 and 396/404 in both A53T ?-syn mutated mouse model
of PD and PD patients in two recent studies (85, 86). ?-Syn also induced GSK-
3beta catalyzed tau phosphorylation in cellular MPP+ and in vivo MPTP models
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(9,87,88). Tau phosphorylation at Ser 262 was found to be promoted by ?-syn
mutations (89). Genetic studies have shown interactions between tau and ?-syn
(90, 91), and A53T mutation was found to induce the fibrillization of tau and ?-
syn in familial PD (92). In addition, genetic variations of ?-syn can modulate the
extent of fibrillization of pathological tau (93).
3. AIMS
This  study  sets  out  to  investigate  whether  the  CNS  expression  of  human  tau
(either wild-type or mutated) leads to neuronal loss and whether this neurotoxicity
is dependent on the ?-synuclein status of the neurons. The neuronal status of ?-
synuclein was varied by giving the injections to either transgenic mice carrying
A30P ?-synuclein mutation or to wild-type mice.
4. MATERIALS AND METHODS
4.1 ANIMALS
In total 37 male mice (7-8 months at the time of the AAV vector injections) were
examined. Mice were divided into two groups with different genotypes in the
study. The first group of mice consisted C57B16/J originating from Charles River
(  Laboratories  Inc.,  Wilmington,  MA,  USA )  with  preserved  mouse  ?-synuclein
gene constituted the wild type ( wt ) group ( n=18 ). The second group of mice (
n= 19 ) carried transgenic human ?-synuclein with the A30P mutation under the
mouse prion protein promoter (94) constituted A30P group. This line was
established as C57BL/6J ×DBA/2J hybrids, thereafter backcrossed for five
generations into the original background C57BL/6J strain (Charles River
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Laboratories Inc.,  Wilmington, MA, USA). The presence of mouse or human ?-
syn was verified with PCR as demonstrated earlier (94).
All the mice were housed individually and kept under controlled conditions
(temperature:  +21°C, light from 7:00 a.m. to 7:00 p.m., humidity 50-60%). Food
and water were freely supplied. All experiments were conducted according to the
Council of Europe and Finnish guidelines, and approved by the National Animal
Experiment Board in Finland.
At  the  end  of  the  study  the  mice  were  deeply  anesthetized  with  a
pentobarbital/chroralhydrate cocktail (60 mg/kg each) and perfused transcardially
with ice-cold heparinized saline followed by 4% paraformaldehyde in PBS for 15
min. The brain was post-fixed for 4 h in the paraformaldehyde solution and then
transferred  to  30%  sucrose  in  PBS  overnight.  Brains  were  frozen  in  a
cryoprotectant and stored under – 20 oC  until  cut  into  35  µm  coronal  brain
sections in 1-in-6 series using a freezing sliding microtome and stored in a
cryoprotectant at 4 °C.
     4.2 INJECTION OF VIRAL VECTORS
The viral vector used in the study was provided by our Swedish collaborators. The
vector used contains the AAV2 inverted terminal repeats pseudotyped in AAV5
capsid, since the AAV5 capsid yields higher transduction efficiency in the brain.
Vector titers were determined by dot-blot analysis to be 3.5E12 and 1.0E12 vector
genomes (vg)/ml for the wild-type and P301S mutant tau vectors, respectively,
and 3.2E13 vg/ml for GFP vector.
Under isoflurane anesthesia (induction 4 %, maintenance 1%, in 30% O2 /70%
N20) the mouse was placed in a mice stereotaxic frame (David Kopf, Tujunga,
CA, USA).  Before opening the scalp, the mouse received a local subcutaneous
injection of 0.5 ml of lidocaine (LidocainR c. adrenalin 120 mg/ml, Orion Pharma,
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Turku, Finland). Each animal received a 1 ?l injection of virus suspension
bilaterally into the dentate gyrus at the following coordinates: AP - 2.0 mm, ML
1.4 mm from bregma, DV 1.6 mm from the dura. The vector was injected at a rate
of  0.1  ?l  per  30  s  with  a  Hamilton  syringe  with  a  fitter  glass  capillary  tip,  after
which the glass capillary was held in place for 5 min before withdrawal. Then the
skin was sutured, and the mouse released from the stereotax. Mice received 5
mg/kg of carprofen (Rimadyl ®, Pfizer) as post-operative analgesic. The animals
were kept in warm incubator (30? C) about 30 min before returning them to clean
home cages.
4.3   CELL COUNTING
4.3.1 Pyramidal cell counting
From each mouse we took one unstained coronal section (Fig. 1B) at the same AP
position (two even space distance from the reference section (Fig. 1A) in rostral
hippocampus where both blades of dentate gyrus (DG) were visible) roughly
corresponding to the level of AAV infusion.
First, all the sections of interest were picked out and let to stay in Phosphate
buffer (PB buffer) overnight at room temperature. The next day, those sections
were mounted on gelatinized slides, and then coverslipped by mounting medium
with 4',6-diamidino-2-phenylindole (DAPi) (VECTASHIELD, Mounting Medium
1.5 mg/ml, Vector Laboratories Inc., Burlingame, CA, USA). The sections were
stained with DAPi to visualize all nucleis with blue fluorescent color. After 24
hours, we started to take photos of the region of interest from both sides of
hippocampus. In order to select the same region, an optical framework was placed
to CA3 cell area in the dentate hilus and then moved to the border of CA2 area
(Fig. 2A and B).
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A digital  photo  was  taken  from the  region  of  interest  from the  hippocampus  on
both sides (Fig. 2C and D). This was done under Olympus BX 40 microscope
(No.  8B07416,  Made  in  Japan).  The  Filter  we  chose  was  WU.  The  software  we
used  was  Viewfinder  Lite  (The  values  we  set  was  like  this:  FL;  Highest
resolution: 2776 × 2074; Exposure Mode: manual; Exposure time: 1/ 1.5;
Sensitivity: 100; Spot: 30 percent; Exposure Adjust: 0).
The final analysis was to count the number of DAPI+ nuclei in this reading frame
on both sides. This has been done in two ways:
(1)  Automatically using the analysis software
This was done by using Photoshop CS3 software. Because each nucleus consists
of 3-4 intense spots on a more or less uniform background, granules and small
spots were not counted as nucleuses. In this step, the stable values were set for the
framework (Feather: 0 px, Style: fixed style, Width: 2500 p, Height: 800 px).
When we started to choose the color, normal style was used. Left and right sides
were counted separately. We always moved the frame to the right border of the
region so that we were always counting the same area (Fig. 2E and F).  After
selecting the area, we started to choose the color from color ranging, and then
began the analysis ( in this step, there were huge number of chosen spots , because
the  software  chose  every  same color  spot  as  a  nuclei,  so  we used  “expand”  and
“contract” to decrease the number of spots to one in one cell.) In the end, we
started to record the measurements.
(2)  Direct visual observation on the computer screen with manual counting.
Left  and  right  sides  were  counted  separately.  In  this  step,  we  first  set  the  same
stable values for the framework on Photoshop CS3 software as it was shown
above, then we started to count the cells in the same area as we chose in counting
by software. Granules and small spots were not counted as pyramidal cells.
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Fig. 1
                 A                                                    B
Fig   1.  Demonstration  of  the  region  of  interest  for  cell  counting.  A: The
reference section. B: Unstained coronal section. Blue frame area is the place
which we took photos from. Red frame area is the place where we counted
pyramidal cells.
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Fig. 2
Fig  2.  A and B: Cresyl violet staining of the region of interest (frame: left and
right sides of hippocampus). Scale bar = 200 µm. C, D, E and F: DAPi staining
of pyramidal cell nuclei. C and D: Amplified frame area of the region of interest
(left and right sides of hippocampus). E and F: Counting area of the frame area
(left and right sides of hippocampus). Scale bar = 50 µm in C, D, E and F.
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4.3.2 Counting of cells expressing Tau 13 and PHF-1
In order to determine whether injected wild-type or mutated human tau protein
becomes hyperphosphorylated, we stained brain sections from 28 tau transduced
animals with the PHF-1 antibody. PHF-1 antibody has the ability of recognizing a
posphorylated epitope of tau protein but displays little cross-reactivity with
normal adult human tau (95). PHF-1 positivity is also considered to indicate an
advanced state toward neurofibrillary tangle formation (96). Here we first counted
the number of Tau-13 positive cells in CA3 area, then we counted the number of
PHF-1 positive cells in the same area from the same section of hippocampus. We
used the percentage of PHF-1 positive cells to Tau-13 positive cells to reflect the
extent of hyperphosphorylation of wild-type or mutated human tau.
PHF-1 slides were made as follows. First, sections of interest were pretreated in
hot citrate solution, and in a small (4 × 6) tray sections were rinsed 3 × 5 min each
in TBS (Tris Buffered Saline; pH = 7.6). Approximately 20 ml / tray. Second, the
sections were incubated with the primary antibody (mouse anti-tau at 1:500; Tau;
MCL;  Peter  Davies  Albert  Einstein  College  of  Medicine,  New  York,  NY,  USA
for 2 weeks at + 4 °C  in TBS-T, pH = 7.6 with azide on a shaker table in the dark
(mouse anti-tau IgG at 1: 500 and 20 µl antibody in 10 ml tris buffered saline with
triton (TBS-T) with azide). After that, sections were rinsed again in Phosphate
buffer saline (PBS) and then incubated with the secondary antibody (Goat anti-
mouse*biotin at 1 : 500; Sigma) for 2 hours. Third, sections were rinsed and put
in Extravidin® (at 1 : 1000) for 2 hours. After that, sections were rinsed 3 × PBS
(5 min each); approximately 20 ml. Visualization of PHF-1 tau was achieved by
incubation with 3,3'-Diaminobenzidine with Nickel (DAB-Ni) solution. In the
end,  we  mounted  the  sections  on  the  slides.  The  method and  process  of  making
tau 13 slides is similar with PHF-1 slides, the only difference being that we made
tau 13 slides by using mouse anti-tau IgG at 1:1000 instead of 1:500 in preparing
PHF-1 slides.
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Digital photos were taken from the region of interest of the hippocampus on both
sides. This was done under Olympus BX 40 microscope (Japan). The software we
used was Viewfinder Lite and the values were set like this: BF; Filter: Wu;
Exposure Mode: Manual; Exposure time: 1/120; Resolution: 1392×1040;
Sensitivity: 100; Spot: 30 percent; Exposure Adjust: 0.
PHF-1 positive cells were counted in 2-3 sections close to the injection site (same
planes  for  all  mice).  A  reading  frame  was  first  placed  around  the  end  of  CA3c
area in the dentate hilus and then moved systematically towards the CA2 border,
so that each section was counted only once. All PHF-1and Tau 13 positive cells
were counted from the selected CA3 region of interest in 28 tau injected animals.
All analyzes were done bilaterally.
4.4 CO-LOCALIZATION ANALYSES
To visualize tau and ?-syn co-localization in the hippocampus, we performed
double fluorescent labeling using a rabbit monoclonal anti-?-syn antibody
(1:1000, SA 3400, Biomol, United Kingdom) and the mouse monoclonal anti-
human Tau13 antibody (Biosite).  The  specificity  of  the  anti-?-syn  antibody was
confirmed by negative staining of sections from ?-syn deficient mice. Before
applying the primary antibody, endogenous peroxidase was quenched by
incubation in 0.1 % H2O2 for 30 min and non-specific binding was blocked in 1%
Bovine serum albumin (BSA) in Kallium phosphate buffer saline with triton
(KPBS-T) for 30 min. The primary antibody was incubated overnight. Sections
were incubated in fluorescent secondary antibodies Alexa 488 (1:250 molecular
probe for tau in double staining) and Alexa 594 (1:250, molecular probe for ?-syn
in double staining) for 2 h at room temperature in darkness. After washing in
TBS-T, the slides were coverslipped by mounting medium with DAPi
(VECTASHIELD®, Mounting Medium 1.5 mg/ml, Vector Laboratories Inc.,
Burlingame, CA, USA).
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Co-localization analyses was done under Zeiss LSM 700 confocal microscope. In
order to know the extent of co-localization, we counted the percentage of ?-syn
tangles in each tau positive cell and its two neighboring ?-syn positive cells in the
CA3 area of hippocampus of mice from each group.
4.5 STATISTICAL ANALYSES
The neuronal cell counts and the area of ?-syn inclusions were analyzed using
two-way ANOVA with genotype and transduction as between-subject factors. All
statistics were run with SPSS 11.0 for Windows software (SPSS Inc., Chicago, IL,
USA).
5      RESULTS
      5.1   TAU TRANSDUCTION IS NOT ASSOCIATED WITH
              MARKED NEURONAL LOSS
In order to assess the extent of neuronal loss in the hippocampus, we calculated
pyramidal  cell  density  in  the  CA3  subregion  which  was  closest  to  the  injection
site. This was done both manually by a human observer blind to the treatment
groups or with an automated image analysis. The correlation coefficient of
pyramidal  cell  count  was  less  than  0.9  from  left  and  right  sides  of  the
hippocampus section in each counting method (Fig. 3), but the replicability of
cell-difference counting results across analysis sessions was always higher than
the  left-right  difference  (Fig.  3  and  4).  The  correlation  coefficient  of  the  results
between the second manual and auto counting was quite close to 1 (Pearson rho =
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0.97, Fig. 4C), which shows high replicability, indicating that the results were
methodologically right.
Although there was a small decline in the pyramidal cell density in A30P mice
receiving wt tau injections (Fig. 5), there was no significant genotype [F(1,30) =
2.7, p = 0.11] or transgene [F(2,30) = 2.7, p = 0.08] main effect or their interaction
[F(2,30) = 0.2, p = 0.85] (Fig. 5A). In addition, using the Fluoro-Jade B marker
for degenerating cells, we found no evidence of apoptotic cells in the hippocampi
of either wild-type of A30P transgenic mice that received tau transductions (data
not shown).
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      Fig. 3
Fig. 3: Correlation coefficient of
pyramidal cell count of left and
right side of the hippocampus
section by different counting
methods. A: Correlation coefficient
of pyramidal cell count of left and
right sides of the hippocampus section
by first manual counting (R2= 0.44,
correlation coefficient R=0.67). B:
Correlation  coefficient  of  pyramidal  cell  count  of  left  and  right  sides  of  the
hippocampus section by second manual counting (R2 = 0.38, correlation
coefficient R = 0.61). C: Correlation coefficient of pyramidal cell count of left
and right sides of the hippocampus section by automatic counting (R2 = 0.31,
correlation coefficient R = 0.55).
26
      Fig. 4
Fig.  4: Correlation coefficient of the
pyramidal cell count from both sides
of the hippocampus section by
different counting methods. A:
Correlation coefficient of the cell count
from both sides of the hippocampus
section by first and second manual
counting (R2 = 0.49, correlation
coefficient R = 0.70). B: Correlation coefficient of the cell count from both sides
of the hippocampus section by first manual and auto counting (R2 = 0.58,
correlation coefficient R = 0.76). C: Correlation coefficient of the cell count from
both sides of the hippocampus section by second manual and automatic counting
(R2 = 0.96, correlation coefficient R = 0.98)
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Fig  5. A: Comparison of different groups in CA3 pyramidal cell density (mean ±
sem). Wt-GFP: 171.50 ± 6.614, wt-wt tau: 160.17 ± 3.103, wt-m tau: 159.63 ±
9.756, tg-GFP: 166.20 ± 6.200, tg-wt tau: 147.43 ± 8.112 and tg-m tau: 159.71 ±
5.630 (P>0.05, ANOVA). B: Comparison  of  pyramidal  cell  density  of  the  CA3
layer  from both  right  and  left  sides  of  the  hippocampus  section  in  tg-wt  tau  and
wt-GFP groups. Scale bar = 50 µm.
5.2   HYPERPHOSPHORYLATION OF WILD-TYPE
          HUMAN TAU IN A30P ?-SYN TRANSGENIC
          MICE
We indeed detected hyperphosphorylated tau in a subset of neuronal cell bodies in
CA3 area in mice with Tau 13 positive cells (Fig. 6A). Since all PHF-1 positive
neurons were also Tau 13 positive, we determined the average ratio of PHF-1
positive neurons of neurons with Tau 13 positive cytoplasm in each group of
mice. Surprisingly, less than 5% of tau-positive neurons transduced with the
P301S mutated tau stained positively for PHF-1 in either wild-type or A30P
mutant mice. In contrast, transduction with wild-type human tau resulted in PHF-
1 positivity in 7% of wild-type and as many as 18% of A30P mice (Fig. 6B). The
ANOVA showed that there was no significant effect of the genotype [F(1,24) =
3.9, p = 0.061] and a significant effect of the injection type [F = 21.0, p = 0.000],
as  well  as  a  significant  effect  of  both  genotype  and  injection  type  [F  =  7.4,  p  =
0.012].
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Fig. 6
A
B
Fig  6. A: Example of PHF positive cells in the CA3 pyramidal cell layer (arrows)
in an A30P transgenic mouse with wild-type human tau transduction. Scale bar =
50 µm. B: Proportion of PHF-positive neurons of Tau 13 positive neurons in the
CA3 area of hippocampus in each group (mean ± sem). * Significantly different
from all other groups (p = 0.012, ANOVA).
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5.3   PRESENCE OF INTRACELLULAR ?-SYN
        INCLUSIONS
?-Syn in the A30P mouse hippocampus is mainly expressed in axon terminals. In
addition, we also detected cytoplasmic ?-syn positive inclusions in pyramidal cell
bodies  (Fig.  7).  We  found  the  size  of  these  cytoplasmic  inclusions  in  randomly
selected 20 Tau13-positive CA3 pyramidal cells and their two neighboring ?-syn
positive cells in A30P mice receiving either wild-type or P301S mutated human
tau transduction by using confocal microscope. By counting the percentage of the
size of ?-syn inclusions of the whole cell body, overall, the tau transduced
neurons did not differ from their neighbouring ?-syn positive neurons [F(1,71) =
2.1, p = 0.15]. However, when the two outliers with extremely large difference
were removed, we found that only in the group of A30P mice that received P301S
mutated tau transduction do we see more a-syn inclusions in the cytoplasm in
Tau13-positive cells than in neighboring ?-syn positive cells [F(1,69) = 6.7, p =
0.012].
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Fig. 7
Fig  7. Influence of tau transduction on cytoplasmic ?-synuclein inclusions.
Confocal image of double-labeled CA3 pyramidal cells from an A30P transgenic
mouse with P301S tau transduction. Red = anti- ?-synuclein, green = anti-Tau 13.
?-Synuclein forms small cytoplasmic inclusions (arrows). Scale bar = 20 µm.
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6 DISCUSSION
In this study we have successfully transferred a target gene of interest selectively
into one desired brain region with an AAV vector. The expression of transduced
gene was detected mostly in axons of the hippocampus, which matches the normal
functions of tau as microtubulus associated protein (97). In addition, we have
demonstrated that this transduction does not induce micro- or astrogliosis.
Therefore, when assessing the possible neuronal loss we could take the total cell
count in a hippocampal CA3 pyramidal cell layer as directly reflecting the number
of neurons. The cell counting results appear reliable, since we found that the
replicability of cell-difference counting results across analysis sessions was
extremely high. In fact, this replicability was even higher than the left-right
difference, which could be explained by the biological variation in the number of
the neurons in different sides of the hippocampus.
Frasier and coworkers (8) found that the A30P transgenic mice had clear motor
symptoms, and showed a four-fold increase in PHF-1 reactivity compared to their
nontransgenic controls, but without any difference in the total levels of tau. Some
researchers have also detected the highest total tau level and the proportion of
neurons which stained positively with phosphorylation specific tau antibodies in
the spinal cord, in which most severe neuron loss and neurodegeneration was also
found in P301S tau transgenic mice (98). However, the appearance of motor
symptoms, high level of tau inclusion, neuron loss and neurodegeneration were
only found in the advanced age of those tau transgenic mice mentioned above. For
example, the cytoplasmic inclusion was showed at 5 months age of P301S
transgenic mice (98). Therefore, one possible reason for no significant neuron loss
and neurodegenerative signs in our wild-type or human A30P transgenic mice
with substantial amounts of human wild-type or P301S mutated tau is that tau
protein did not have enough time to be exposed to tau-kinases to be
hyperphosphorylated and aggregated into filaments. Nonetheless, one still could
see the trend that those groups with the highest expression of PHF-1 positive
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neurons (for example, tg-wt tau) also have the lowest neuronal counts in the CA3
subregion of the hippocampus.
We did not detect significant tau hyperphosphorylation in either wild-type or
A30P ?-syn transgenic mice transduced with P301S mutated vector, but a lot of
tau hyperphosporylation was shown in A30P mice receiving wild-type human tau
vector. This result is contrary to the idea that the ability of tau to bind to
microtubuli will be reduced by the familial frontotemporal dementia linked
mutations at the sites of P301L and P301S, which induces tau polymerization into
aggregation (99). However, there is also evidence indicating that the P301L
mutation prevented tau binding to ?-syn (100). It is possible that the P301S
mutation also has a similar effect. One possible mechanism of ?-syn induced tau
aggregation is that it may act as a chaperone protein to facilitate tau
hyperphosphorylation at Ser396/404 residues (the PHF-1 binding site) by altering
the presentation of these serine residues to the related reactive kinases such as
Cdk5, PKA, GSK3? and MAPK(9). So tau hyperphosphorylation would be down-
regulated by these enzymes when the binding of tau with ?-syn is impaired.
We have detected ?-syn inclusions in tau positive pyramidal cells. Conversely, the
presence of ?-syn could also promote tau aggregation (101), which indicates that
tau and ?-syn would have the ability of inducing fibrillization of each other.
However, we only detected significantly more ?-syn inclusions in tau positive
cells than their neighbouring ?-syn positive cells in A30P mice that tranduced
with P301S mutated tau. One possible explanation is that tau reacts with ?-syn, so
that the ?-syn epitope gets masked from the antibody, but the cross-reaction does
not happen between P301S tau and A30P a-syn, which is consistent with the PHF-
1 staining result showing that P301S tau does not show hyperphospholyration in
A30P mice, but wild-type tau does.
In conclusion, the present study demonstrates that tau and ?-syn proteins interact
in vivo and that their interaction promotes ?-syn aggregation and tau
hyperphosphorylation. However, this interaction inducing tau
hyperphosphorylation is dependent on specific binding site on tau, and that
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mutation at the 301 site prevents this interaction. It would be interesting in future
studies to specifically compare ?-syn and tau co-occurrence in the brains of
P301L or P301S mutant carriers and those with other tauopathies.
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